About us
Superior cancer therapeutics using transformative innovations.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technologies.
Vision
VERAXA will deliver the next wave of smart cancer therapies with curative potential and far less side effects.
Mission
VERAXA aims to be at the forefront of this smartest generation of antibody-based cancer therapeutics.
We develop cancer programs that are based on:
antibodies selected for the highest therapeutic value
an advanced generation of ADCs with never seen flexibility and ease of production
novel ADCs and our novel BiTAC antibody formats that elevate safety and efficacy to new levels
Managed by an experienced leadership team
Management
Board of Directors
Clinical Advisory Board
Investors
VERAXA is a privately held company. Main shareholder is the Swiss company Xlife Sciences AG. Other shareholders are the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBL Technology Transfer GmbH (EMBLEM), private investors, founders and management.



Business Combination Agreement
On April 22, 2025, VERAXA entered into a definitive business combination agreement (the "Business Combination Agreement") with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, "Voyager"). Upon closing of the Business Combination Agreement, VERAXA is expected to become a publicly traded company listed on NASDAQ.
For more information, please go to: Voyager Transaction
Join our team
We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.
With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.